John Kenny
ORASURE TECHNOLOGIESAbout John P. Kenny
John P. Kenny is an independent Class I director of OraSure Technologies, Inc. (OSUR), appointed in September 2024; he is age 56 and brings more than 30 years of leadership across in vitro diagnostics, molecular, microbiology, anatomic pathology, and lab services. He previously served as CEO of Meridian Bioscience and held senior roles at Siemens Healthcare, Becton Dickinson, Danaher, and Quest Diagnostics; he holds a bachelor’s degree in management from Kettering University . He is independent under Nasdaq/SEC rules and is nominated for re‑election in 2025 for a term expiring at the 2028 annual meeting .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Meridian Bioscience | Chief Executive Officer | Not disclosed | Grew sales and earnings above market and bolstered product line |
| Siemens Healthcare | SVP & GM, North America | Not disclosed | Commercial leadership |
| Becton Dickinson, Diagnostic Systems | VP & GM, U.S. Region | Not disclosed | Product launches and portfolio planning |
| Danaher Corporation | Executive roles | Not disclosed | Marketing, lifecycle management, new product development |
| Quest Diagnostics | Executive roles | Not disclosed | M&A and commercial execution |
External Roles
| Organization | Type | Role | Committees |
|---|---|---|---|
| QuantumSi (Nasdaq: QSI) | Public | Independent Director | Not disclosed |
| DCN Dx (Martis Capital-owned) | Private | Independent Director | Not disclosed |
Board Governance
- Committee leadership: Chair, Nominating & Corporate Governance Committee; Member, Compensation Committee; independent director .
- Independence: Determined independent in Q1 2025 annual review; all standing committees comprised solely of independent directors .
- Attendance and engagement: Board held 13 meetings in 2024; each director attended >75% of Board and committee meetings; executive sessions at regular meetings .
- Annual meeting attendance: Five of six directors attended the 2024 annual meeting; directors are expected to attend .
- Ownership/retention: Directors subject to stock ownership guidelines (3x annual cash fees, rising to 4x effective Jan 1, 2025) and must retain 50% of net shares until compliant .
- Trading policies: Preclearance and quarterly windows; strict prohibition on short sales, hedging, margin purchases, and pledging of OSUR stock .
Fixed Compensation
| Component | Amount/Policy | Notes |
|---|---|---|
| 2024 Cash Fees (Kenny) | $19,110 | Partial-year service since Sept 2024 |
| 2024 Stock Awards (Kenny) | $100,000 (restricted stock) | Initial director grant upon joining |
| Standard Annual Fees (2024) | Board member $55,000; Board Chair +$25,000; Audit/Comp/N&CG Chair +$20,000 each; Non-chair committee member +$5,000 | Paid quarterly in arrears |
| 2025 Fee Changes | Board Chair fee increased to $50,000 | Effective Jan 1, 2025 |
Performance Compensation
| Equity Award Type | Value | Vesting | Key Terms |
|---|---|---|---|
| Initial Grant (upon joining Board) | $100,000 RS | Cliff vests 2 years after appointment (joined Sept 2024) | Change-of-control: immediate vesting of unvested RS |
| Annual Grant (2024 policy) | $105,000 RS for non-employee directors | Vests on or before next annual meeting | Chair additional $25,000 (eliminated in 2025) |
| Annual Grant (2025 policy) | $185,000 RS for non-employee directors | Vests on or before next annual meeting | Chair equity eliminated; cash Chair fee increased |
| Deferred Compensation | Eligible to defer director fees and RS under non-qualified plan | Plan terms allow elections on fees/RS with distribution options |
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public boards | QuantumSi (QSI): independent director |
| Private boards | DCN Dx (Martis Capital): independent director |
| Compensation committee interlocks | None reported; no insider participation or interlocks disclosed |
| Related-party transactions | None since Jan 1, 2024; Audit Committee pre-approves any related-party transactions |
Expertise & Qualifications
- Executive-level experience as CEO and GM in diagnostics across IVD, molecular, and lab services; deep commercial and portfolio management expertise .
- 30+ years industry experience including Siemens Healthcare, BD, Danaher, Quest Diagnostics; BA in Management from Kettering University .
- Board skills matrix shows business operations, global business, commercial execution, and M&A coverage among directors; Kenny contributes healthcare and leadership expertise .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| John P. Kenny | 70,915 | <1% | Includes 23,256 unvested restricted shares |
- Hedging/pledging: Prohibited under OSUR policy for directors and employees .
- Ownership guidelines: 3x annual cash fees as of Dec 31 each year; increased to 4x effective Jan 1, 2025; retention of 50% of net shares until compliant .
- Compliance status: As of Dec 31, 2024, two non-employee directors were not yet in compliance due to recent appointments; company provides up to five years to reach compliance .
Governance Assessment
- Strengths: Independent status; chairs Nominating & Corporate Governance and serves on Compensation Committee, signaling strong governance involvement . Robust policies against hedging/pledging and structured ownership guidelines align director interests with shareholders . Board attendance was strong (>75%), and shareholder support for pay improved sharply (Say‑on‑Pay 93% approval in 2024 versus 66% in 2023) after program refinements .
- Potential risks/RED FLAGS: New director with partial-year service; initial ownership likely still ramping toward new 4x fee guideline—company notes recent appointees may be non-compliant pending the five‑year window . Multiple board commitments (QSI and DCN Dx) elevate time demands; monitor for overboarding and any emerging business overlaps. Equity plan amendments increased share reserve by 6,000,000 shares for grants through 2026, implying continued equity-based dilution—appropriate context for investors tracking board-equity alignment and burn rate (burn 2.7% in 2024; overhang 10.36%) .
Overall, Kenny’s governance roles and independence, combined with strict trading/ownership policies, support investor confidence; watch near-term ownership progression to the 4x fee guideline and time commitments across boards.